Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
France Targets Shein, Temu With Fast-Fashion Fees 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Toyota Global Sales Fall as China Demand Slumps 
CIA-Linked Investor Helped Quantum Systems Expand in US 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
 2018 Annual Meeting - EconoTimes)
Add as a preferred source on Google
RANCHO CORDOVA, Calif., March 28, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) today announced that two late-breaking abstracts involving the use of Cesca’s X-Series™ technologies for cell processing have been accepted for presentation as posters at the ISCT 2018 Annual Meeting, which is being held May 2-5, 2018 at the Palais des Congrès de Montréal in Montreal, Québec. Details of the poster presentations are as follows:
Abstract 2963114: Novel buoyancy based cell selection: X-BACS™ Technology
Poster number/abstract ID number: 380
Poster Session 2: May 4, 2018, 5:00-6:30PM
Abstract 2963911: Quick and easy method for removal of DMSO from thawed cellular products
Poster number/abstract ID number: 381
Poster Session 2: May 4, 2018, 5:00-6:30PM
About the International Society for Cellular Therapy (ISCT) Annual Meeting
ISCT is a global society of clinicians, regulators, technologists, and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients' lives. ISCT members gain access to an influential global community of peers, experts, and organizations invested in cell therapy. ISCT offers a unique collaboration between academia, regulatory bodies, and industry partners in cell therapy translation.
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
